209 related articles for article (PubMed ID: 32846211)
1. Natural tyrosine kinase inhibitors acting on the epidermal growth factor receptor: Their relevance for cancer therapy.
Liang Y; Zhang T; Zhang J
Pharmacol Res; 2020 Nov; 161():105164. PubMed ID: 32846211
[TBL] [Abstract][Full Text] [Related]
2. Discovery of an EGFR tyrosine kinase inhibitor from Ilex latifolia in breast cancer therapy.
Wang C; Wang R; Chen Y; Wang L; Zhou S; Wang H
Bioorg Med Chem Lett; 2019 Jun; 29(11):1282-1290. PubMed ID: 30962086
[TBL] [Abstract][Full Text] [Related]
3. A review on progression of epidermal growth factor receptor (EGFR) inhibitors as an efficient approach in cancer targeted therapy.
Ayati A; Moghimi S; Salarinejad S; Safavi M; Pouramiri B; Foroumadi A
Bioorg Chem; 2020 Jun; 99():103811. PubMed ID: 32278207
[TBL] [Abstract][Full Text] [Related]
4. Epidermal growth factor receptor targeting in cancer: a review of trends and strategies.
Yewale C; Baradia D; Vhora I; Patil S; Misra A
Biomaterials; 2013 Nov; 34(34):8690-707. PubMed ID: 23953842
[TBL] [Abstract][Full Text] [Related]
5. Review on Epidermal Growth Factor Receptor (EGFR) Structure, Signaling Pathways, Interactions, and Recent Updates of EGFR Inhibitors.
Sabbah DA; Hajjo R; Sweidan K
Curr Top Med Chem; 2020; 20(10):815-834. PubMed ID: 32124699
[TBL] [Abstract][Full Text] [Related]
6. Combined Treatment with Triptolide and Tyrosine Kinase Inhibitors Synergistically Enhances Apoptosis in Non-small Cell Lung Cancer H1975 Cells but Not H1299 Cells through EGFR/Akt Pathway.
Tong X; Jiang P; Li Y; Guo L; Zhang HM; Zhang BK; Yan M
Chem Pharm Bull (Tokyo); 2019 Aug; 67(8):864-871. PubMed ID: 31142691
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological background of EGFR targeting.
Castillo L; Etienne-Grimaldi MC; Fischel JL; Formento P; Magné N; Milano G
Ann Oncol; 2004 Jul; 15(7):1007-12. PubMed ID: 15205192
[TBL] [Abstract][Full Text] [Related]
8. Targeting EGFR and IGF 1R: a promising combination therapy for metastatic cancer.
Singh I; Amin H; Rah B; Goswami A
Front Biosci (Schol Ed); 2013 Jan; 5(1):231-46. PubMed ID: 23277048
[TBL] [Abstract][Full Text] [Related]
9. Celastrol improves the therapeutic efficacy of EGFR-TKIs for non-small-cell lung cancer by overcoming EGFR T790M drug resistance.
Wang Y; Liu Q; Chen H; You J; Peng B; Cao F; Zhang X; Chen Q; Uzan G; Xu L; Zhang D
Anticancer Drugs; 2018 Sep; 29(8):748-755. PubMed ID: 29927769
[TBL] [Abstract][Full Text] [Related]
10. Natural Products Targeting EGFR Signaling Pathways as Potential Anticancer Drugs.
Wang X; Xu L; Lao Y; Zhang H; Xu H
Curr Protein Pept Sci; 2018 Feb; 19(4):380-388. PubMed ID: 28059040
[TBL] [Abstract][Full Text] [Related]
11. Combined inhibition of MEK and PI3K pathways overcomes acquired resistance to EGFR-TKIs in non-small cell lung cancer.
Sato H; Yamamoto H; Sakaguchi M; Shien K; Tomida S; Shien T; Ikeda H; Hatono M; Torigoe H; Namba K; Yoshioka T; Kurihara E; Ogoshi Y; Takahashi Y; Soh J; Toyooka S
Cancer Sci; 2018 Oct; 109(10):3183-3196. PubMed ID: 30098066
[TBL] [Abstract][Full Text] [Related]
12. Natural products derived from traditional chinese medicine as novel inhibitors of the epidermal growth factor receptor.
Sertel S; Plinkert PK; Efferth T
Comb Chem High Throughput Screen; 2010 Dec; 13(10):849-54. PubMed ID: 20883187
[TBL] [Abstract][Full Text] [Related]
13. Novel substituted quinazolines for potent EGFR tyrosine kinase inhibitors.
Cruz-López O; Conejo-García A; Núñez MC; Kimatrai M; García-Rubiño ME; Morales F; Gómez-Pérez V; Campos JM
Curr Med Chem; 2011; 18(7):943-63. PubMed ID: 21254978
[TBL] [Abstract][Full Text] [Related]
14. EGFR-TKIs resistance via EGFR-independent signaling pathways.
Liu Q; Yu S; Zhao W; Qin S; Chu Q; Wu K
Mol Cancer; 2018 Feb; 17(1):53. PubMed ID: 29455669
[TBL] [Abstract][Full Text] [Related]
15. Discovery of new thieno[3,2-d]pyrimidine derivatives targeting EGFR
Chen Y; Yang L; Qiao H; Cheng Z; Xie J; Zhou W; Huang X; Jiang Y; Yu B; Zhao W
Eur J Med Chem; 2020 Aug; 199():112388. PubMed ID: 32402937
[TBL] [Abstract][Full Text] [Related]
16. Crosstalk between Epidermal Growth Factor Receptors (EGFR) and integrins in resistance to EGFR tyrosine kinase inhibitors (TKIs) in solid tumors.
Javadi S; Zhiani M; Mousavi MA; Fathi M
Eur J Cell Biol; 2020 May; 99(4):151083. PubMed ID: 32381360
[TBL] [Abstract][Full Text] [Related]
17. Epidermal growth factor receptor: pathway, therapies, and pipeline.
Goffin JR; Zbuk K
Clin Ther; 2013 Sep; 35(9):1282-303. PubMed ID: 24054705
[TBL] [Abstract][Full Text] [Related]
18. Tumor-targeting of EGFR inhibitors by hypoxia-mediated activation.
Karnthaler-Benbakka C; Groza D; Kryeziu K; Pichler V; Roller A; Berger W; Heffeter P; Kowol CR
Angew Chem Int Ed Engl; 2014 Nov; 53(47):12930-12935. PubMed ID: 25079700
[TBL] [Abstract][Full Text] [Related]
19. Cyclosporine A sensitizes human non-small cell lung cancer cells to gefitinib through inhibition of STAT3.
Shou J; You L; Yao J; Xie J; Jing J; Jing Z; Jiang L; Sui X; Pan H; Han W
Cancer Lett; 2016 Aug; 379(1):124-33. PubMed ID: 27264264
[TBL] [Abstract][Full Text] [Related]
20. New Directions for Advanced Targeting Strategies of EGFR Signaling in Cancer.
Zhou Y; Takahashi JI; Sakurai H
Biol Pharm Bull; 2024; 47(5):895-903. PubMed ID: 38692865
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
